Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test

Rebecca A. Lafleur, Ronald Wilson, Daniel Morgan, Angela N. Henderson-Redmond

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cannabinoids have shown promise for the treatment of intractable pain states and may represent an alternative pharmacotherapy for pain management. A growing body of clinical evidence suggests a role for sex in pain perception and in cannabinoid response. We examined cannabinoid sensitivity and tolerance in male and female mice expressing a desensitization-resistant form (S426A/S430A) of the cannabinoid type 1 receptor (CB 1 R). Mice were assessed for acute and inflammatory nociceptive behaviors in the formalin test following pretreatment with either vehicle or mixed CB 1 R/CB 2 R agonists, Δ-9-tetrahydrocannabinol ( 9 -THC) (1-6 mg/kg) or CP 55,940 (0.06-0.2 mg/kg). Tolerance to the effects of 6 mg/kg 9 -THC or 0.1 mg/kg CP 55,940 was examined by the formalin test following chronic daily dosing. Female mice showed decreased sensitivity to the effects of 9 -THC and CP 55,940 compared with male mice. The S426A/S430A mutation increased the attenuation of nociceptive behaviors for both agonists in both sexes. Female mice displayed delayed tolerance to 9 -THC compared with male mice, whereas the S426A/S430A mutation conferred a delay in tolerance to 9 -THC in both sexes. Male S426A/S430A mutant mice also display resistance to tolerance to CP 55,940 compared with wild-type controls. This study demonstrates sex and genotype differences in response for two different cannabinoid agonists. The results underscore the importance of including both male and female mice in preclinical studies of pain and cannabinoid pharmacology.

Original languageEnglish (US)
Pages (from-to)447-452
Number of pages6
JournalNeuroReport
Volume29
Issue number6
DOIs
StatePublished - Jan 1 2018

Fingerprint

Dronabinol
Pain Measurement
Sex Characteristics
Cannabinoids
Cannabinoid Receptors
Cannabinoid Receptor Agonists
Intractable Pain
Mutation
Pain Perception
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
Pain Management
Genotype
Pharmacology
Drug Therapy
Pain

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

@article{4ffb6ff94ac545a4b0486892f8cae8ac,
title = "Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test",
abstract = "Cannabinoids have shown promise for the treatment of intractable pain states and may represent an alternative pharmacotherapy for pain management. A growing body of clinical evidence suggests a role for sex in pain perception and in cannabinoid response. We examined cannabinoid sensitivity and tolerance in male and female mice expressing a desensitization-resistant form (S426A/S430A) of the cannabinoid type 1 receptor (CB 1 R). Mice were assessed for acute and inflammatory nociceptive behaviors in the formalin test following pretreatment with either vehicle or mixed CB 1 R/CB 2 R agonists, Δ-9-tetrahydrocannabinol ( 9 -THC) (1-6 mg/kg) or CP 55,940 (0.06-0.2 mg/kg). Tolerance to the effects of 6 mg/kg 9 -THC or 0.1 mg/kg CP 55,940 was examined by the formalin test following chronic daily dosing. Female mice showed decreased sensitivity to the effects of 9 -THC and CP 55,940 compared with male mice. The S426A/S430A mutation increased the attenuation of nociceptive behaviors for both agonists in both sexes. Female mice displayed delayed tolerance to 9 -THC compared with male mice, whereas the S426A/S430A mutation conferred a delay in tolerance to 9 -THC in both sexes. Male S426A/S430A mutant mice also display resistance to tolerance to CP 55,940 compared with wild-type controls. This study demonstrates sex and genotype differences in response for two different cannabinoid agonists. The results underscore the importance of including both male and female mice in preclinical studies of pain and cannabinoid pharmacology.",
author = "Lafleur, {Rebecca A.} and Ronald Wilson and Daniel Morgan and Henderson-Redmond, {Angela N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/WNR.0000000000000993",
language = "English (US)",
volume = "29",
pages = "447--452",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test. / Lafleur, Rebecca A.; Wilson, Ronald; Morgan, Daniel; Henderson-Redmond, Angela N.

In: NeuroReport, Vol. 29, No. 6, 01.01.2018, p. 447-452.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test

AU - Lafleur, Rebecca A.

AU - Wilson, Ronald

AU - Morgan, Daniel

AU - Henderson-Redmond, Angela N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cannabinoids have shown promise for the treatment of intractable pain states and may represent an alternative pharmacotherapy for pain management. A growing body of clinical evidence suggests a role for sex in pain perception and in cannabinoid response. We examined cannabinoid sensitivity and tolerance in male and female mice expressing a desensitization-resistant form (S426A/S430A) of the cannabinoid type 1 receptor (CB 1 R). Mice were assessed for acute and inflammatory nociceptive behaviors in the formalin test following pretreatment with either vehicle or mixed CB 1 R/CB 2 R agonists, Δ-9-tetrahydrocannabinol ( 9 -THC) (1-6 mg/kg) or CP 55,940 (0.06-0.2 mg/kg). Tolerance to the effects of 6 mg/kg 9 -THC or 0.1 mg/kg CP 55,940 was examined by the formalin test following chronic daily dosing. Female mice showed decreased sensitivity to the effects of 9 -THC and CP 55,940 compared with male mice. The S426A/S430A mutation increased the attenuation of nociceptive behaviors for both agonists in both sexes. Female mice displayed delayed tolerance to 9 -THC compared with male mice, whereas the S426A/S430A mutation conferred a delay in tolerance to 9 -THC in both sexes. Male S426A/S430A mutant mice also display resistance to tolerance to CP 55,940 compared with wild-type controls. This study demonstrates sex and genotype differences in response for two different cannabinoid agonists. The results underscore the importance of including both male and female mice in preclinical studies of pain and cannabinoid pharmacology.

AB - Cannabinoids have shown promise for the treatment of intractable pain states and may represent an alternative pharmacotherapy for pain management. A growing body of clinical evidence suggests a role for sex in pain perception and in cannabinoid response. We examined cannabinoid sensitivity and tolerance in male and female mice expressing a desensitization-resistant form (S426A/S430A) of the cannabinoid type 1 receptor (CB 1 R). Mice were assessed for acute and inflammatory nociceptive behaviors in the formalin test following pretreatment with either vehicle or mixed CB 1 R/CB 2 R agonists, Δ-9-tetrahydrocannabinol ( 9 -THC) (1-6 mg/kg) or CP 55,940 (0.06-0.2 mg/kg). Tolerance to the effects of 6 mg/kg 9 -THC or 0.1 mg/kg CP 55,940 was examined by the formalin test following chronic daily dosing. Female mice showed decreased sensitivity to the effects of 9 -THC and CP 55,940 compared with male mice. The S426A/S430A mutation increased the attenuation of nociceptive behaviors for both agonists in both sexes. Female mice displayed delayed tolerance to 9 -THC compared with male mice, whereas the S426A/S430A mutation conferred a delay in tolerance to 9 -THC in both sexes. Male S426A/S430A mutant mice also display resistance to tolerance to CP 55,940 compared with wild-type controls. This study demonstrates sex and genotype differences in response for two different cannabinoid agonists. The results underscore the importance of including both male and female mice in preclinical studies of pain and cannabinoid pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=85045020748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045020748&partnerID=8YFLogxK

U2 - 10.1097/WNR.0000000000000993

DO - 10.1097/WNR.0000000000000993

M3 - Article

C2 - 29461336

AN - SCOPUS:85045020748

VL - 29

SP - 447

EP - 452

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 6

ER -